

11 Publication number:

0 356 223 A3

(2)

#### **EUROPEAN PATENT APPLICATION**

2) Application number: 89308555.5

② Date of filing: 23.08.89

(i) Int. Cl.<sup>5</sup>: **C07K 5/02**, C07C 125/065, C07C 143/74, C07C 153/057, C07D 213/40, C07H 13/04, C07F 9/28, C07F 9/09, A61K 37/64, A61K 31/16, A61K 31/395

Priority: 24.08.88 US 236495 28.03.89 US 328645

- 43 Date of publication of application: 28.02.90 Bulletin 90/09
- Designated Contracting States:
   AT BE CH DE ES FR GB GR IT LI LU NL SE
- Date of deferred publication of the search report:
  21.08.91 Bulletin 91/34

Applicant: MERCK & CO. INC. 126, East Lincoln Avenue P.O. Box 2000 Rahway New Jersey 07065-0900(US)

(2) Inventor: Desolms, S. Jane 735 Port Indian Road Norristown PA 19403(US) Inventor: Huff, Joel R. 738 Bergey Mill Road Lederach PA 19450(US) Inventor: Vacca, Joseph P. 766 Eisenhauer Drive Telford PA 18969(US) Inventor: Sigal, Irving S.

Deceased(US)
Inventor: Darke, Paul L.
434 West Walnut Street
North Wales PA 19454(US)
Inventor: Young, Steven D.
128 Mark Drive
Lansdale PA 19446(US)

Representative: Hesketh, Alan, Dr. et al European Patent Department Merck & Co., Inc. Terlings Park Eastwick Road Harlow Essex, CM20 2QR(GB)

 $\ensuremath{\mathfrak{G}}$  HIV protease inhibitors useful for the treatment of aids.

© Compounds of the form, A-G-B-B-J wherein A is an amine prote

wherein A is an amine protecting group not useful or commonly employed in peptide synthesis, G a dipeptide isostere, B an amino acid or analog thereof, and J a small terminal group are described. These compounds are useful in the inhibition of HIV protease, the prevention or treatment of infection by

HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.



European Patent
Office
PARTIAL EUROPEAN SEARCH REPORT
which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

Application number

EP 89 30 8555

	DOCUMENTS CON	SIDERED TO BE RELEVAN	IT	]
Category	Citation of document v of rel	vith indication, where appropriate, evant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
X	B.E. EVANS et a lled synthesis	, American Chemical  1.: "A stereocontro  of hydroxyethylene  eres using novel,  yl epoxides and  lkyl) upsilon-	1-3,6, 7,10, 11,14- 17,24- 26	C 07 K 5/02 C 07 C 125/065 C 07 C 143/74 C 07 C 153/057 C 07 D 213/40 C 07 H 13/04 C 07 F 9/28 C 07 F 9/09 A 61 K 37/64 A 61 K 31/16 A 61 K 31/395 A 61 K 31/66 C 07 K 5/06
	-	- <b>-</b>	27-36	
INCOM The Searct the provision out a mean Claims sea Claims sea Claims not Reason for	PROCEEDINGS OF T PEPTIDE SYMPOSIU PIECE Chemical Illinois, US;  IPLETE SEARCH  To Division considers that the presections of the European Patent Conveningful search into the state of the auropean content convenients of the auropean content of the auropean content convenients and 18-23	TRE AND FUNCTION - THE NINTH AMERICAN M, pages 743-746, Co., Rockford,  ./.  Int European patent application does not contion to such an extent that it is not possible to the basis of some of the claims.  7,10,11,14,15,16,17,	le to carry	TECHNICAL FIELDS SEARCHED (Int. CI.4)  C 07 K C 07 C C 07 D A 61 K
X: parti	Place of search THE HAGUE  CATEGORY OF CITED DOCL	E : earlier pate	nt document, b	Examiner GROENENDIJK  ring the invention sut published on, or
Y : parti docu A : techi O : non-	cularly relevant if combined w iment of the same category nological background written disclosure mediate document	D: document of L: document of L:	ited in the app	lication sasons it family, corresponding



	CLAIMS INCURRING FEES						
		Success extent prolication compassed of the time of filling more than ten claims					
The	The present European patent application comprised of the time of filling more than ten claims.						
£		All claims fees have even paid within the prescribed time limit. The present European search report has been drawn up for all claims.					
(		Only part of the claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid.					
		namely claims:					
[		No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.					
х	LAC	CK OF UNITY OF INVENTION					
		Division considers that the present European patent application does not comply with the requirement of unity of					
		d relates to several inventions or groups of inventions.					
name	siy:						
		See sheet -B-					
		• • • • • • • • • • • • • • • • • • • •					
		· ·					
		·					
[	$\supset$	All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.					
ſ	_	Only part of the further search fees have been paid within the fixed time limit. The present European search					
į		report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid,					
		namely claims:					
(	K	None of the further search fees has been paid within the fixed time ilmit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first					
		mentioned in the claims 1-3,6,7,10,11,14,15,16,17,24-36(partially) and namely claims: 18-23					



### LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirement of unity of Invention and relates to several inventions or groups of inventions.

- 1. Claims 1-3,6,7,10,11,14,15,16,17,24-36(all partially) and 18-23: Compounds of formula 1 wherein Q=-CH(OH)-CH<sub>2</sub>-,Z=O, and Rg=(subst.) aralkyl and their pharmaceutical compositions.
- 2. Claims 1-3,6,7,10,11,14,15,16,17,24-36(all partially) and 4,5,8,9,12,13: Other compounds of formula 1 and their pharmaceutical compositions.



## PARTIAL EUROPEAN SEARCH REPORT

EP 89 30 8555 -2-

	DOCUMENTS CONSIDERED TO BE RELEVANT	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)	
Category	Citation of document with indication, where appropriate, of relevant passages		
	B.E. EVANS et al.: "A stereocontro- lled synthesis of hydroxyethylene dipeptide isosteres using novel, chiral aminoalkyl epoxides; new renin inhibitor analogs"		
Y	* Entire article *	1-3,6, 7,10, 14-17, 24-26	•
1		L, 33	
x	EP-A-0 206 090 (MERCK & CO.)		TECHNICAL FIELDS SEARCHED (Int. CI.4)
	* Entire document *	1-3,6, 7,10, 11,14- 17,24- 26	
A		27-36·	
Y	NATURE, vol. 329, 15th October 1987, pages 654-656; I. KATOH et al.: "Inhibiton of retroviral protease activity by an aspartyl proteinase inhibitor"		
	* Entire article *	27-36	
D,A	MARKETLETTER, 30th November 1987, pages 26-27, IMS World Publications Ltd; "Aids products in development"		
	* Entire article *	24,26, 28,30, 32,34, 36	
	<del></del>		
D,A	GENETIC ENGINEERING NEWS, January 1988, pages 23,29; S.P. DELCO: "AIDS diagnostic and therapeutic market potential ./.		



# PARTIAL EUROPEAN SEARCH REPORT

Application number

EP 89 30 8555 -3-

	DOCUMENTS CONSIDERED TO BE RELEVANT	CLASSIFICATION OF TH APPLICATION (Int. CI.4	
ategory	Gitation of document with indication, where appropriate, of relevant passages	Relevant to claim	
	continues to grow"		
	* Entire article *	24,26, 28,30, 32,34, 36	
		-	TECHNICAL FIELDS SEARCHED (Int. CI.4)
		-	



The formula of claim 1 is extremely broad and is lacking an invariable structural entity common to all the compounds covered by it. Besides the formula covers well-known (intermediate) products (e.g.EP 209897 from the applicant, EP 212203 and the documents cited in the search report). Therefore no common inventive concept can be acknowledged for the compounds of this formula.

Moreover the extensive lists of substituents and their cascading prohibits the Searching Authority to perform a complete search or even to make an exhaustive list of subdivisions according to unifying structural characteristics.

For this reasons the application does not meet the requirements

laid down in Art. 82 and 84 EPC.

On the basis of the examples the search has been directed to the subject as defined in the supplemental sheet B and restricted to the examples covered by this subject and close analogs of them. The actual subject 2 contains still distinct subjects which lack a common unifying structural entity.

Applicant is invited, in case he seeks patent protection beyond the first subject to specify the distinct unitary subjects amongst the subject matter of the actual subject 2. If the applicant pays just one or more search fees without any specification of the desired subject matter to be searched the Searching Authority will be compelled to make a further subdivision of the actual second subject and remit a new

partial search report.

THIS PAGE BLANK (USPTO)